Nebivolol Stada (Nebivolol)

Nebivolol is a selective β1‑adrenergic blocker indicated for cardiovascular conditions that benefit from blood‑pressure reduction and improved cardiac output.

• Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension.
• Heart failure: improves left‑ventricular ejection fraction and reduces symptoms in patients with chronic heart failure with reduced ejection fraction.
• Post‑myocardial infarction: helps to prevent recurrent cardiovascular events in patients after a heart attack.

• Nebivolol selectively antagonizes β1‑adrenergic receptors, reducing heart rate and myocardial contractility, which lowers cardiac output and blood pressure. In addition, it stimulates endothelial nitric oxide synthase, causing nitric‑oxide‑mediated vasodilation that further contributes to its antihypertensive effect without significant β2 blockade.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Headache: mild to moderate headache reported during early therapy.
• Dizziness: transient light‑headedness, especially when standing quickly.
• Fatigue: general tiredness or lack of energy.
• Bradycardia: slower than normal heart rate.
• Nausea: occasional stomach upset.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Hypotension: significant drop in blood pressure causing fainting.
• Heart block: conduction abnormalities on ECG.
• Bronchospasm: airway constriction, particularly in patients with asthma.
• Allergic reaction: rash, itching, or swelling indicating hypersensitivity.

Before initiating Nebivolol therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: assess baseline and periodic readings to ensure adequate control.
• Cardiac function assessment: evaluate heart rate and ECG for bradyarrhythmias.
• Concomitant beta‑blocker use: avoid additive effects that may cause excessive heart rate reduction.
• Asthma or chronic obstructive pulmonary disease: use with caution due to possible bronchospasm.
• Renal impairment: dose adjustment may be needed in severe renal dysfunction.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other beta‑blockers: combined use may cause profound bradycardia and hypotension.
• Calcium‑channel blockers (verapamil, diltiazem): increase nebivolol plasma levels and risk of heart block.
• Anti‑arrhythmic class IA agents (quinidine, procainamide): may exacerbate conduction disturbances.
• Potent CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol concentrations.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: additive blood‑pressure lowering effect; monitor for hypotension.

• Diuretics: may enhance orthostatic hypotension; assess volume status.
• NSAIDs: can blunt antihypertensive response; watch blood‑pressure trends.